



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 12th February 2021

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

BSE Code: 524396; NSE Script Code: BIOFILCHEM, ISIN No INE829A01014

Sub: - Outcome of the Board Meeting held on 12th February 2021.

With reference to the above-mentioned subject, we would like to inform that Board of the Directors of the Company in their meeting (No. 04/2020-2021) held today i.e. Friday 12th day of February 2021, has approved Un-Audited Financial Result and Limited Review Report thereon for the Quarter and nine months ended on 31st December, 2020. Copy of result being sent separately

The meeting of Board of Directors was commenced at 4.30 p.m. and concluded at 5.50 p.m.

This is for your information and record

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
DIN: 00028819





BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 12th February 2021

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Sub: Submission of Un-Audited Financial Result for the quarter and nine months ended on 31st December, 2020 together with Limited Review Report thereon

BSE Code: 524396; NSE Script Code: BIOFILCHEM, ISIN No INE829A01014

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter and nine months ended on 31st December, 2020 duly approved by the Board of Directors of the Company at its meeting held today i.e. on Friday, 12th February, 2021. **Copy of Unaudited Financial Results is enclosed with this letter (searchable PDF mode).**

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.

Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN No. 00028819)



Encl: a/a

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2020

(Amount in Lakhs except EPS)

S. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Previous Year ended on 31/03/2020
		3 months ended on 31/12/2020	Previous 3 months ended on 30/09/2020	Corresponding 3 months ended on 31/12/2019	Year to date figures for Current period ended 31/12/2020	Year to date figures for Previous period ended 31/12/2019	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	319.20	1601.86	1,275.20	2,151.17	2,597.50	2969.02
II	Other Income	2.21	14.59	8.86	80.42	13.33	17.15
III	Total Income (I+II)	321.42	1,616.45	1,284.06	2,231.59	2,610.83	2,986.17
IV	Expenses						
	(a) Cost of materials consumed	276.19	138.95	83.75	554.79	268.02	405.66
	(b) Purchases of stock-in-trade	2.18	75.45	11.20	1,287.53	2,156.17	2159.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-72.03	1,252.53	1,096.81	58.33	(122.28)	(34.23)
	(d) Employee benefits expense	23.66	23.25	32.50	63.67	72.93	86.34
	(e) Depreciation and amortisation expense	10.87	2.00	2.87	15.32	9.73	12.24
	(f) Finance Cost	1.16	10.88	9.45	22.25	28.03	40.83
	(f) Other Expenses	28.13	20.69	24.56	64.09	92.27	169.47
	Total Expenses	270.16	1,523.74	1,261.12	2,065.97	2,504.87	2,839.76
V	Profit/(Loss) before Exceptional Items and tax (III-IV)	51.25	92.71	22.94	165.63	105.96	146.41
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit (+)/ Loss (-) before tax (V-VI)	51.25	92.71	22.94	165.63	105.96	146.41
VIII	Tax expense	0.00	0.00	0.00	0.00	0.00	0.00
	Current Tax	0.00	0.00	0.00	0.00	0.00	25.69
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit/(Loss) for the period (from continuing operation(VII-VIII))	51.25	92.71	22.94	165.63	105.96	120.72
X	Profit/(Loss) from discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) for the period (IX+XII)	51.25	92.71	22.94	165.63	105.96	120.72
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	A. (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	2.62
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the Period (XIII+XIV) comprising Profit (Loss) and other comprehensive income for the period	51.25	92.71	22.94	165.63	105.96	123.35
XVI	Paid-up equity share capital @ Rs. 10/- each	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII	Reserve excluding Revaluation Reserves as per balance sheet of previous year						-515.27
XVIII	Earnings Per Equity Share (for continuing operation)	0.00	0.00	0.00	0.00	0.00	0.00
	a) BASIC	0.31	0.57	0.14	1.02	0.65	0.76
	b) DILUTED	0.31	0.57	0.14	1.02	0.65	0.76
XIX	Earnings Per Equity Share (for discontinued operation)						
	a) BASIC	0.00	0.00	0.00	0.00	0.00	0.00
	b) DILUTED	0.00	0.00	0.00	0.00	0.00	0.00
XX	Earnings Per Equity Share (for continuing & discontinued operation)						
	a) BASIC	0.31	0.57	0.14	1.02	0.65	0.76
	b) DILUTED	0.31	0.57	0.14	1.02	0.65	0.76



Note :

- 1 The above results for the Quarter and Nine Month ended December 31, 2020 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 12th February, 2021. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 The Financial Results of the Company has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- 3 a. Pharma Product
b. Chemicals Division

- 4 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors


- 5 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 6 The Earning Per Shares (Basic and Diluted) for the interim period have not been annualized.


For and on behalf of the Board

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Date: 12/02/2021

Place : Indore


RAMESH SHAH
Managing Director (DIN: 00028849)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcpcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2020

(Amount in Lakhs)

S.N.	Particulars	Quarter Ended			Year to date figures		Year Ended
		December 31,	September 30,	December 31,	Current Period ended December 31, 2020	Previous Period ended December 31, 2019	March 31,
		2020	2020	2019			2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Division	77.32	1384.61	1148.23	1486.68	2202.28	2436.17
	Chemicals Division	241.88	217.25	126.97	664.49	395.22	532.85
	Plastic Division	0.00	0.00	0.00	0.00	0.00	0.00
	Others	2.21	14.59	7.29		10.72	19.77
	Gross Turnover	321.42	1616.45	1282.49	2151.17	2608.22	2988.79
2	Segment Results						
	Pharma Division	48.43	64.19	22.47	102.70	98.35	91.41
	Chemicals Division	3.99	30.51	1.77	68.51	19.30	67.60
	Plastic Division	0.00	0.00	0.00	0.00	-4.63	-6.81
	Others	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit Before Interest & Tax	52.42	94.71	24.24	171.22	113.02	152.20
	Interest Income	0.00	0.00	1.57	0.00	2.61	2.16
	Interest Expenses	1.16	2.00	2.86	5.60	9.67	5.33
	Other Un-allocable Income net of Expenditure						0.00
	Profit Before Tax	51.25	92.71	22.94	165.62	105.96	149.03
	Provision for current tax	0.00	0.00	0.00	0.00	0.00	24.88
	Item Related Earlier Year	0.00	0.00	0.00	0.00	0.00	0.81
	Profit After Tax	51.25	92.71	22.94	165.62	105.96	123.35
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	681.72	2203.60	3440.20	681.72	3440.20	3017.03
	Chemicals Division	1292.01	1250.61	1170.88	1292.01	1170.88	1219.47
	Plastic Division				0.00		0.00
	Others						
	Total (A)	1973.73	3454.22	4611.08	1973.73	4611.08	4236.49
	Segment Liabilities (B)						
	Pharma Division	71.19	1609.82	2753.52	71.19	2753.52	2404.93
	Chemicals Division	252.06	212.52	337.43	252.06	337.43	343.24
	Plastic Division	0.00	0.00	0.00	0.00	0.00	0.00
	Others	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	323.25	1822.34	3090.95	323.25	3090.95	2748.18
4	Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division	610.53	593.78	686.67	610.53	686.67	612.09
	Chemicals Division	1039.95	1038.09	833.45	1039.95	833.45	876.22
	Plastic Division	0.00	0.00	0.00	0.00	0.00	0.00
	Others	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	1650.48	1631.87	1520.12	1650.48	1520.12	1488.32

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


Date: 12.02.2021

Place: Indore

RAMESH SHAH

MANAGING DIRECTOR

DIN: 00028819





Limited Review Report
(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements))

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore

Review report to **Biofil Chemicals and Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited Financial results (" the statement") of **Biofil Chemicals and Pharmaceuticals Limited ("the company")** for the quarter ended 31st December, 2020 and year to date from 01st April, 2020 to 31st December, 2020.
This Statement, which is the responsibility of the Company's Management and approved by Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard- Ind AS 34 " Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (" the listing regulations"). Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 12.02.2021

For Maheshwari & Gupta

CA Sunil Maheshwari
Partner
M No.403346

UDIN:21403346AAAAEA2076